ABL Diagnostics Société anonyme
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more
ABL Diagnostics Société anonyme (9BK0) - Total Assets
Latest total assets as of December 2024: €11.81 Million EUR
Based on the latest financial reports, ABL Diagnostics Société anonyme (9BK0) holds total assets worth €11.81 Million EUR as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ABL Diagnostics Société anonyme - Total Assets Trend (2021–2024)
This chart illustrates how ABL Diagnostics Société anonyme’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ABL Diagnostics Société anonyme - Asset Composition Analysis
Current Asset Composition (December 2024)
ABL Diagnostics Société anonyme's total assets of €11.81 Million consist of 71.4% current assets and 28.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.0% |
| Accounts Receivable | €3.23 Million | 27.4% |
| Inventory | €699.41K | 5.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.71 Million | 22.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how ABL Diagnostics Société anonyme's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABL Diagnostics Société anonyme's current assets represent 71.4% of total assets in 2024, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 4.0% of total assets in 2024, down from 99.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 27.4% of total assets.
ABL Diagnostics Société anonyme Competitors by Total Assets
Key competitors of ABL Diagnostics Société anonyme based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
UCrest Bhd
KLSE:0005
|
Malaysia | RM48.46 Million |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
China | CN¥265.74 Million |
|
BIT Computer Co. Ltd
KQ:032850
|
Korea | ₩82.38 Billion |
|
ezCaretech Co. LTD
KQ:099750
|
Korea | ₩56.71 Billion |
|
SyntekaBio Inc
KQ:226330
|
Korea | ₩33.49 Billion |
|
Carelabs Co.Ltd
KQ:263700
|
Korea | ₩105.15 Billion |
|
Shanghai Kingstar Winning Software
SHE:300253
|
China | CN¥8.35 Billion |
|
Longmaster Information Tech
SHE:300288
|
China | CN¥1.33 Billion |
ABL Diagnostics Société anonyme - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - ABL Diagnostics Société anonyme generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, ABL Diagnostics Société anonyme generates $ 2.41 in net profit.
ABL Diagnostics Société anonyme - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.79 | 2.06 | - |
| Quick Ratio | 4.39 | 1.92 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €6.67 Million | € 5.26 Million | - |
ABL Diagnostics Société anonyme - Advanced Valuation Insights
This section examines the relationship between ABL Diagnostics Société anonyme's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -20.8% |
| Total Assets | €11.81 Million |
| Market Capitalization | $371.65K USD |
Valuation Analysis
Below Book Valuation: The market values ABL Diagnostics Société anonyme's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ABL Diagnostics Société anonyme's assets decreased by 20.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ABL Diagnostics Société anonyme (2021–2024)
The table below shows the annual total assets of ABL Diagnostics Société anonyme from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €11.81 Million | -20.76% |
| 2023-12-31 | €14.90 Million | -3.28% |
| 2022-12-31 | €15.41 Million | +467.87% |
| 2021-12-31 | €2.71 Million | -- |